(Q38200670)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24684351%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24684351%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24684351%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

T M E Davis

series ordinal

1

1 reference

30 August 2017

16 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24684351%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24684351%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24684351%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

891-899

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24684351%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24684351%20AND%20SRC:MED&resulttype=core&format=json

A review of the efficacy and safety of oral antidiabetic drugs

12 March 2020

cites work

1 reference

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice

21 January 2018

1 reference

Selection and dosing of medications for management of diabetes in patients with advanced kidney disease

21 January 2018

1 reference

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results

21 January 2018

1 reference

Drug-target residence time and its implications for lead optimization

21 January 2018

1 reference

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects

21 January 2018

1 reference

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system

21 January 2018

1 reference

The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.

21 January 2018

1 reference

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

21 January 2018

1 reference

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

21 January 2018

1 reference

Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

21 January 2018

1 reference

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

21 January 2018

1 reference

Clinical pharmacokinetics and pharmacodynamics of vildagliptin

21 January 2018

1 reference

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

21 January 2018

1 reference

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency

21 January 2018

1 reference

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

21 January 2018

1 reference

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.

21 January 2018

1 reference

Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis

21 January 2018

1 reference

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

21 January 2018

1 reference

DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.

21 January 2018

1 reference

Hypoglycaemia in Type 2 diabetes

21 January 2018

1 reference

Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research

21 January 2018

1 reference

The epidemiology of pancreatitis and pancreatic cancer

21 January 2018

1 reference

Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

21 January 2018

1 reference

The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses

21 January 2018

1 reference

Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.

21 January 2018

1 reference

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

21 January 2018

1 reference

Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials

21 January 2018

1 reference

Validity of meta-analysis in diabetes: we need to be aware of its limitations

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12295

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24684351%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference